Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Exclusive Story A Fresh IPO That Long-Term Investors Shouldn't IgnoreAuthor: Jordan Chussler. Date Posted: 1/14/2026. 
Key Points - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. Even so, some recently listed stocks deserve attention from more conservative, buy-and-hold investors because they may justify a place in long-term portfolios. Gold is up almost $2,000 an ounce in the past year, catching many on Wall Street by surprise. But one analyst predicted the move. Right after Trump's election, he called for gold to pass $3,200, and it happened within two days. He said it would soar past $4,100, and it did within two months. He predicted $5,000 early in 2026, and that just happened. Now he says gold is headed to $7,000 soon with $10,000 on the near horizon. But despite gold's run, there's a way to make even more, an approach that has delivered 31, 65, even 469 times higher gains than gold itself. Learn the critical details now. That may be true for one biotechnology company in the healthcare sector that just went public. Last Year's IPO Success Stories Last year is a strong example of why newly public companies shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. While short-term speculators benefited from its roughly 359% gain within 30 days of listing on Nasdaq, longer-term holders have also seen substantial returns. Others, such as Medline (NASDAQ: MDLN), disprove the idea that all IPOs are high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already boasts a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its widely available bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, began trading on Jan. 9 and is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with a targeting module that seeks out particular cells (for example, cancer cells) to deliver localized radiation, minimizing harm to healthy tissue compared with some conventional radiation therapies. Industry consultancy Grand View Research estimates the global nuclear medicine market at nearly $18 billion in 2024 and forecasts it will reach almost $35 billion by 2030—a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States the predominant player—an important point for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Biotechnology Wall Street expects biotech IPOs to rebound in 2026 after funding changes under the Trump administration slowed healthcare-sector listings in 2025. Aktis, which debuted on Nasdaq on Jan. 9 as the first biotech IPO of 2026, completed one of the largest recent raises for a biotech offering. The company raised $318 million in its IPO and has a market cap of about $3.34 billion. According to the company's prospectus, management includes experts in drug development, approval and commercialization; team members have helped bring 14 currently FDA‑approved products to market. Aktis develops targeted alpha radiopharmaceuticals—a class of precision cancer drugs using proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not deter Eli Lilly (NYSE: LLY) from anchoring its IPO. According to Reuters, Eli Lilly purchased $100 million worth of AKTS shares in the offering. That investment builds on a 2024 collaboration between the companies to develop tumor-targeting radiopharmaceuticals, under which Lilly committed $60 million in cash and made an equity investment, with potential milestone payments that could exceed $1 billion. The significance of Lilly's backing is notable. Valued at about $1.01 trillion, Eli Lilly is one of the largest pharma companies by market cap; its net income jumped nearly 109% year over year from 2023 to 2024. That momentum is likely to be reflected when Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million purchase of AKTS shares, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
